View Older Stories

Apr 2, 2026 08:30AM Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

Mar 26, 2026 05:15PM Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

Mar 10, 2026 08:32AM Dermata appoints Kyra Peckaitis as VP of marketing for Tome skincare launch

Mar 10, 2026 08:30AM Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

Mar 5, 2026 09:00AM Dermata Opens a New Chapter with the Release of Tome Skincare

Jan 20, 2026 08:05AM Dermata receives Australian patent for Spongilla acne treatment technology

Jan 20, 2026 08:05AM Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Dec 29, 2025 04:05PM Dermata Therapeutics closes $12.4 million private placement

Dec 29, 2025 04:05PM Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 24, 2025 08:00AM Dermata Therapeutics raises $4.1 million in private placement

Dec 24, 2025 08:00AM Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025 08:00AM A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Nov 14, 2025 05:28PM Dermata Therapeutics, Inc (DRMA) Misses Q3 EPS by 165c

Nov 14, 2025 04:05PM Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 2, 2025 08:02AM Dermata receives Australian patent acceptance for acne treatment

Oct 2, 2025 08:00AM Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Sep 17, 2025 01:00AM Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 10, 2025 08:01AM Dermata Therapeutics shifts focus to over-the-counter skin products

Sep 10, 2025 08:00AM Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Aug 13, 2025 05:44PM Dermata Therapeutics, Inc (DRMA) Misses Q2 EPS by 166c

Aug 13, 2025 05:00PM Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 8, 2025 08:01AM Dermata (DRMA) receives Australian patent for topical botulinum toxin treatment

Jul 8, 2025 08:00AM Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

May 21, 2025 07:54AM Dermata Therapeutics In (DRMA) PT Lowered to $3 at Maxim Group

May 14, 2025 09:00AM Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 15, 2025 08:35AM Dermata's (DRMA) XYNGARI Phase 3 trial shows significant difference

Apr 15, 2025 08:30AM Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Mar 27, 2025 08:15PM Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025 08:01AM Dermata Therapeutics, Inc (DRMA) Reports XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 27, 2025 07:55AM Dermata Therapeutics, Inc (DRMA) Halted, News Pending

Mar 17, 2025 04:16PM Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Feb 25, 2025 07:59AM Dermata (DRMA) Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Feb 25, 2025 07:58AM Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jan 29, 2025 04:05PM Dermata to Present on BioPub on January 31, 2025

Jan 23, 2025 04:15PM Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025 08:04AM Dermata Therapeutics, Inc (DRMA) Announces $2.55M Private Placement

Jan 22, 2025 08:00AM Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 21, 2025 08:03AM Dermata (DRMA) and Revance (RVNC) Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari with Daxxify

Jan 21, 2025 08:00AM Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dec 16, 2024 09:00AM Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 10, 2024 09:08AM Dermata Therapeutics, Inc (DRMA) Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 10, 2024 09:00AM Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 3, 2024 09:00AM Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 13, 2024 04:15PM Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Oct 8, 2024 04:15PM Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Sep 19, 2024 04:49PM Dermata Therapeutics, Inc (DRMA) Files for 5.87M Share Offering by Selling Stockholders

Sep 17, 2024 05:15PM Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024 09:00PM Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 5, 2024 04:05PM Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 21, 2024 07:50AM Dermata Therapeutics In (DRMA) PT Lowered to $6 at Maxim Group

View Older Stories